In summary, this study revealed that the IL7/CCL19 production technology confers potent antitumor efficacy on CAR-T targeting EGFRvIII or HER2 and can be applicable to CAR-T against intractable solid cancers such as glioblastoma and pancreatic cancer. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.